This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eli Lilly (LLY) Stock Moves -0.23%: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $364.99, marking a -0.23% move from the previous day.
SNY or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SNY vs. LLY: Which Stock Is the Better Value Option?
Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More
by Zacks Equity Research
Updates from Gilead Sciences (GILD) and ProQR (PRQR) are the key highlights from the biotech sector during the past week.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $365.22, marking a +0.09% move from the previous day.
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $364.88, marking a -0.82% move from the previous day.
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly
by Zacks Equity Research
ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.
The Zacks Analyst Blog Highlights United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly
by Zacks Equity Research
United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly are part of the Zacks top Analyst Blog.
Roche (RHHBY) Actemra Gets FDA Nod for Adults With COVID-19
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for Actemra (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalized adult patients. The drug was earlier granted an EUA.
3 Drug Stocks Most Wall Street Analysts Are Bullish About
by Ekta Bagri
Here we present three drug and biotech stocks, UTHR, ITCI and IMCR, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.
Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Lilly (LLY) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Eli Lilly (LLY) Stock Moves -0.58%: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $357.78, marking a -0.58% move from the previous day.
Time to Buy Eli Lilly (LLY) and AbbVie (ABBV) Stock for 2023?
by Shaun Pruitt
AbbVie's valuation, in particular, makes it a potentially strong candidate for 2023, while Eli Lilly's growth could support its stock next year.
Pharma Stock Roundup: LLY's 2023 View, MRK-MRNA Joint Cancer Vaccine Data & More
by Kinjel Shah
Eli Lilly (LLY) gives its financial guidance for 2023. Merck (MRK) and Moderna's (MRNA) mRNA-based cancer vaccine shows positive results in a joint study.
SNY vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. LLY: Which Stock Is the Better Value Option?
Eli Lilly (LLY) 2023 Guidance Falls Short, Stock Declines
by Zacks Equity Research
Eli Lilly's (LLY) 2023 EPS guidance falls short of the Zacks Consensus Estimates and our model estimates. The company plans to launch four new drugs next year.
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $367.25, marking a +1.73% move from the previous day.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Zacks Market Edge Highlights: LLY, PFE, JPM, ULTA, QQQ
by Zacks Equity Research
LLY, PFE, JPM, ULTA, QQQ have been highlighted in this Market Edge article.
Will There be a Recession in 2023?
by Tracey Ryniec
Tracey Ryniec and John Blank are back with their annual look at the economy and how to invest in the new year.
Relative Strength Found Within These 3 Medical Stocks
by Derek Lewis
The Zacks Medical sector has modestly outperformed the S&P 500 over the last three months, up more than 7% vs. the general market's 4% gain.
Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal
by Zacks Equity Research
Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.
Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal
by Kinjel Shah
Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.
Why Is Lilly (LLY) Up 4.5% Since Last Earnings Report?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Lilly's (LLY) Donanemab Betters Biogen's Alzheimer's Drug
by Zacks Equity Research
Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY) donanemab leads to a significant reduction of amyloid buildup in the brain and P-tau in the blood after six months.